Foundayo Alternatives & Comparison
How Foundayo (orforglipron) compares to Zepbound, Wegovy, Saxenda — mechanism, trial weight-loss results, and cost — plus where to compare vetted providers.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Foundayo Alternatives Compared
Injectable dual GIP/GLP-1 agonist with the largest average weight loss of any approved option
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects.
Zepbound (tirzepatide) is the magnitude winner — SURMOUNT-1 delivered ~22.5% TBWL at 72 weeks via a dual GIP/GLP-1 injectable, roughly double Foundayo (orforglipron) ATTAIN-1 ~11% on a once-daily oral pill. But Foundayo wins on convenience: no needles, no fasting protocol, and dose flexibility. Lilly makes both, with cash pricing similar at list. Pick Zepbound for maximal weight loss; pick Foundayo if injection or food-timing rules are deal-breakers.
Full Zepbound vs Foundayo comparison →Injectable GLP-1-only option with the longest real-world weight-management track record
Wegovy delivers semaglutide 2.4mg — the highest approved dose — via once-weekly self-injection. It mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake.
Wegovy (injectable semaglutide) edges Foundayo (oral orforglipron) by roughly 3-4 percentage points on weight loss and is the only one with proven cardiovascular benefit — SELECT cut MACE 20% in non-diabetic obesity. Foundayo wins on convenience: a daily pill with no food restriction, no injection, no cold-chain handling. Cash prices are comparable via NovoCare and LillyDirect. Choose injection-plus-CV-data or pill-plus-no-needles.
Full Wegovy vs Foundayo comparison →Older once-daily injectable GLP-1 for patients who don't want a once-weekly injection
Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours.
Foundayo (orforglipron) is the stronger choice for most adults: ATTAIN-1 showed -11.1% body weight at 72 weeks on the 17.2 mg max dose vs Saxenda's roughly -7-8% in SCALE Obesity (Pi-Sunyer 2015), and a daily pill with no food restriction beats a daily subcutaneous injection on adherence. Saxenda holds two niches Foundayo cannot: a pediatric indication for adolescents 12 and older, and a short half-life that makes pre-pregnancy washout planning straightforward. Both are once-daily; neither matches once-weekly tirzepatide on raw magnitude.
Full Saxenda vs Foundayo comparison →Compare compounded Tirzepatide providers
Compounded tirzepatide runs a median of $275/month across 219 vetted-provider price points (range $99–$1,100). Featured partners below, ranked by our partner-economics ordering.
Compare every Foundayo provider
See current pricing, verification status, form, and states served across every vetted provider in one place.